Results 81 to 90 of about 11,074 (164)

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, Volume 15, Issue 3, Page 206-226, September 2026.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

Metabolites of alectinib in human: their identification and pharmacological activity

, 2017
Two metabolites (M4 and M1b) in plasma and four metabolites (M4, M6, M1a and M1b) in faeces were detected through the human ADME study following a single oral administration of [14C]alectinib, a small-molecule anaplastic lymphoma kinase inhibitor, to ...
Li Yu, Kosuke Kawashima, Miyuki Yoshida, Kenji Takanashi, Martin Binder, Yukako Tachibana, Mika Sato-Nakai, Peter N. Morcos, Toshito Nakagawa, David J Moore   +9 more
core   +1 more source

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports [PDF]

IntroductionAberrant expression of anaplastic lymphoma kinase (ALK) is found in 3%–7% of patients with non-small cell lung cancer (NSCLC). Alectinib is a tyrosine kinase inhibitor used as first-line treatment targeting ALK-positive tumors.
Paul Wheatley-Price, Sara Moore, Boaz Wong, Hely Shah, Harman Sekhon   +4 more
core   +1 more source

A Process for Preparing Alectinib or a Pharmaceutically Acceptable Salt Thereof

, 2019
The present invention relates to a process for preparing Alectinib or a pharmaceutically acceptable salt thereof.
Gupta, N., Tomar, Azim, Cabri W, Lahiri, V.S, S., A.   +8 more
core   +1 more source

Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature

SAGE Open Medical Case Reports, 2020
With the advent of targeted therapy for non-small-cell lung cancer, there are many new available treatment options for patients whose cancer harbors an actionable mutation or alteration.
Karan Seegobin, Umair Majeed, Yanyan Lou, Yujie Zhao, Rami Manochakian   +4 more
doaj   +1 more source

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement

Frontiers in Oncology
BackgroundAlectinib has demonstrated promising disease-free survival (DFS) benefit for early-stage non-small cell lung cancer (NSCLC) patients with ALK rearrangement positive in phase 3 ALINA trial.
Zeng-Hao Chang, Teng-Fei Zhu, Wei Ou, Hao Jiang, Si-Yu Wang   +4 more
doaj   +1 more source

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

BMC Cancer
Objectives To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).
Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang   +4 more
doaj   +1 more source

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

, 2016
Alectinib, a novel alternative anaplastic lymphoma kinase (ALK) inhibitor, is highly effective against ALK-positive non-small cell lung cancer (NSCLC) and is well tolerated. Molecular targeted agents generally have little contribution to alopecia.
Shigeru Sasaki, Nodoka Sekiguchi, Tomonobu Koizumi, Daisuke Gomi, Takashi Kobayashi, Keiko Mamiya, Toshirou Fukushima, Akiyuki Sakamoto   +7 more
core   +1 more source

An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 2H6-alectinib and alectinib in human plasma to support a microtracer food-effect trial

A liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantification of 2H6-alectinib and alectinib was developed and validated for the support of a pilot microtracer food-effect trial.
Ali, M. I. Mohmaed, Steeghs, N., Aardenburg, L. G. J., Huitema, A. D. R., Afd Pharmacoepi & Clinical Pharmacology, van der Heijden, L. T., Pharmacoepidemiology and Clinical Pharmacology, Beijnen, J. H., Rosing, H., Tibben, M. M.   +9 more
core   +1 more source

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib [PDF]

, 2016
The central nervous system (CNS) is an important and increasingly recognized site of treatment failure in anaplastic lymphoma kinase (ALK)-positive, non–small cell lung cancer (NSCLC) patients receiving ALK inhibitors. In this report, we describe two ALK-
Hu, Ranliang, Shih, Helen A., Logan, Jennifer, Shaw, Alice T., Chi, Andrew S., Oh, Kevin S., Gainor, Justin F., Brastianos, Priscilla K.   +7 more
core   +1 more source